ngp 555
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2015 (NCT02534480)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Beta amyloid A4 proteinINHIBITOR
APP inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ngp 555
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02537938 | Phase 1 | Jan 1, 2016 | NeuroGenetic Pharmaceuticals Inc, WCCT Global |
| NCT02534480 | Phase 1 | Mar 1, 2015 | NeuroGenetic Pharmaceuticals Inc, WCCT Global |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NeuroGenetic Pharmaceuticals Inc | For profit | 2 | 2 | 1 | 2015 |
| WCCT Global | For profit | 2 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1